Skip to content

Advertisement

  • Poster presentation
  • Open Access

P07 - Treatment load in the therapy management of allergic rhinitis: a UK retrospective database study

  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8 and
  • 9
Clinical and Translational Allergy20144 (Suppl 1) :P62

https://doi.org/10.1186/2045-7022-4-S1-P62

  • Published:

Keywords

  • Allergic Rhinitis
  • Allergic Rhinitis
  • Symptom Relief
  • Seasonal Allergic Rhinitis
  • Perennial Allergic Rhinitis

Background

Allergic rhinitis (AR) is poorly controlled. Treated patients, even those on multiple therapies still experience symptoms. In a UK survey, 70.5% of moderate-to-severe AR patients took ≥2 medications (either Rx or over the counter) in an attempt to achieve better and faster symptom relief.

Aim

To explore the extent of co-prescribing by UK general practitioners (GPs) during the hay-fever season in patients with seasonal AR (SAR), perennial AR (PAR), and comorbid asthma.

Method

A retrospective database study using the Optimum Patient Care Research Database consisting of data extracted from GP records supplemented with patient-reported outcomes from questionnaires. Patients included in the analysis had a recorded AR diagnosis and ≥1 AR therapy scripts during 1st March 2010 to 31st Augu37st 2010.

Results

In all, 22,381 AR patients were included. Results are summarized in the table.

Table 1

1st March 2010 to 31st August 2010

 

SAR (n=16187)

PAR (n=6194)

Therapy, n (%)

Season Start

Season End

Season Start

Season End

Single therapy

10776 (65.5)

8850 (54.7)

4764 (76.9)

2974 (48.0)

Dual therapy

3782 (23.4)

5213 (32.2)

1172 (18.9)

2445 (39.5)

Triple therapy

1615 (10.0)

2062 (12.7)

244 (3.9)

694 (11.2)

Quadruple therapy

24 (0.1)

62 (0.4)

14 (0.2)

77 (1.2)

5 therapies

0 (0.0)

0 (0.0)

0 (0.0)

4 (0.1)

Total on combinations

5421 (33.5)

7337 (45.3)

1430 (23.0)

3220 (52.0)

Season End, n (%)

Asthma (n=8787)

Non Asthma (n=13594)

 

SAR

PAR

SAR

PAR

Combination therapy

Start of season

End of season

1536 (24.6)

2296 (41.6)

780 (23.9)

1805 (55.2)

3885 (36.4)

5041 (47.2)

650 (22.2)

1415 (48.4)

Conclusion

In contrast to previous surveys, these data relate to prescriptions only and show a high level of co-prescribing behavior among UK GPs. There was a significant shift to combination therapy during the season, particularly for PAR patients, with strong co-prescription evident regardless of asthma co-morbidity. These data indicate that (i) UK GPs are aware that current therapy provides insufficient symptom relief, (ii) that AR is a costly disease to treat requiring several GP visits over the season for therapy modification and (iii) there is a need for an AR therapy which provides more complete symptom relief.

Authors’ Affiliations

(1)
Research in Real Life, Cambridge, United Kingdom
(2)
University of Aberdeen, Aberdeen, United Kingdom
(3)
RNTNE Hospital, London, United Kingdom
(4)
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
(5)
University Hospital Ghent, Ghent, Belgium
(6)
Imperial College of Medicine, London, United Kingdom
(7)
Meda Pharmaceuticals, London, United Kingdom
(8)
Research in Real Life, Norwich, United Kingdom
(9)
East Midlands Strategic Health Authority, Leicester, United Kingdom

Copyright

Advertisement